Oncology Dermatology Medication Enrollment Form

Medications A-O

(Braftovi, Cotellic, Erivedge, Keytruda, Mekinist, Mektovi, Odomzo, Opdivo, Opdualag)



Fax Referral To: 1-888-435-1256 Email Referral To: Customer.ServiceFax@CVSHealth.com Phone: 1-855-539-4712

	Six Sir	nple Steps to Sub	omitting a Referral				
PATIENT INFORM	MATION (Complete or includ	e demographic sheet)					
_	ON (Complete or include dem						
Patient Name:				male			
Address:							
			t (to cell # provided below) 0 Email (to email provid				
			re, you are consenting to receive automated calls, emails a Standard data rates apply. Message frequency varies. If una				
	narmacy will attempt to contact by		standard data rates appry. Message frequency varies. If dis	able to contact via			
			ternate Phone:				
Primary Phone: Alternate Phone: Alternate Phone: Primary Language:							
Parent/Caregiver/Leg	al Guardian Name (Last, First	:):	Relationship Patient:				
2 PRESCRIBER INF	ORMATION						
Prescriber's Name:			State License #:				
NPI #:	DEA #: Gı	oup or Hospital:					
Address:		Ci	ity, State, ZIP Code: : Contact's Phone:				
			d insurance cards with this form, if available (fror	•			
2 DIAGNOSIS AND	CLINICAL INFORMATI	ON Needs by Date: _	Ship to: \square Patient \square Office \square Other: $_$				
<u>Diagnosis (ICD-10):</u>		,					
	iption		Code: Description				
	iption		Code: Description				
	rmation: Allergies:	······································	Weight:lb/kg Height:in/cm				
5 PRESCRIPTION							
DRUG NAME	STRENGTH		SIG/DIRECTIONS QUA	ANTITY/REFILLS			
	☐ 50 mg		aily in combination with Mektovi 45 mg PO twice daily	0			
Braftovi	75 mg	│	aily in combination with Erbitux	Quantity: Refills:			
Cotellic	20 mg	3 tablets PO once d	laily days 1-21, off 7 days. Recycle every 28 days.	Quantity: Refills:			
	209	Other:					
Erivedge	150 mg	1 capsule PO once daily Quantity:					
	100 mg	Other: Refills: Quantity:					
☐ Keytruda	100 mg/4 mL		☐ 200 mg IV every 3 weeks ☐ 400 mg IV every 6 weeks ☐ Other:				
Поупиц	100 1119/ 11112	Other:					
Mekinist	2 mg	1 tablet PO once daily Quantity:					
WCKIIIISC	☐ 0.5 mg	☐ Other: Refills:					
☐ Mektovi	15 mg		45 mg PO twice daily in combination with Braftovi 450 mg PO once daily Quantity:				
IVICKTOVI	Other:						
Odomzo 200 mg		1 capsule PO once daily		Quantity:			
Odomizo	200 Hig	Other:		Refills:			
	☐ 40 mg/4 mL			Quantity:			
Opdivo	100 mg/10 mL		vo weeks	Refills:			
	240 mg/24 mL	☐ 1 mg/kg IV every 3 weeks x 4 doses ☐ Other:					
		Other.					
Opdualag			and 160 mag valationals IV avanu 4 washe	Quantity:			
(nivolumab and relatimab-rmbw)	240 mg-80 mg/20 mL	480 mg nivolumab and 160 mg relatlimab IV every 4 weeks		Refills:			
Patient is interested in patient support programs STAMP SIGNATURE NOT ALLOWED Ancillary supplies and kits provided as needed for administration							
Patient is interested in patient support programs STAMP SIGNATURE NOT ALLOWED Anciliary supplies and kits provided as needed for administration 6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)							
"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute May Substitute / Product Selection Permitted / Substitution Permissible							
	re:	Date:	Prescriber's Signature:	Date:			
<u> </u>							
CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" ATTN: New York and Iowa providers, please submit electronic prescription							

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

Oncology Dermatology Medication Enrollment Form

Medications P-Z

(Poteligeo, Tafinlar, Tecentriq, Yervoy, Zelboraf, Zolinza)

	Ple	ase Complete Patient a	and Prescriber Information	
Patient Name:		Patient DOB: _	Patient Phone	Number
Prescriber Na	ame:		Prescriber Phone:	
5 PRESCRIP	TION INFORMATIO	N		
DRUG NAME	STRENGTH	SIC	G/DIRECTIONS	QUANTITY/REFILLS
Poteligeo	20 mg/5 mL	☐ 1 mg/kg IV Days 1, 8, 15, 22 ☐ 1 mg/kg IV every 2 weeks ☐ Other:	x1 cycle	Quantity: Refills:
Tafinlar	50 mg 75 mg	2 capsules PO twice daily Other:		Quantity: Refills:
Tecentriq	840 mg/14 mL	840 mg IV every 2 weeks Other:		Quantity: Refills:
☐ Yervoy	☐ 50 mg/10 mL ☐ 200 mg/40 mL	3 mg/kg IV every 3 weeks 10 mg/kg IV every 3 weeks 10 mg/kg IV every 12 week Other:	x 4 doses s x 4 doses s	Quantity: Refills:
Zelboraf	240 mg	4 tablets PO twice daily Other:		Quantity: Refills:
Zolinza	100 mg	4 capsules PO once daily Other:		Quantity: Refills:
PRESCRIPTIO	NS DRUG NAM	ME/STRENGTH	SIG/DIRECTIONS	QUANTITY/REFILLS
Rx 1	Other:	Oth	er:	Quantity: Refills:
Rx 2	Other:	Oth	er:	Quantity: Refills:
Rx 3	Ondansetron Promethazine	☐ Oth	er:	Quantity: Refills:
Patient is interest	ted in patient support progra		RE NOT ALLOWED Ancillary supplies and k	
	6 PRESCRIBER	SIGNATURE REQUIRED	(STAMP SIGNATURE NOT	ALLOWED)
"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute Prescriber's Signature:			May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature:	
			ATTN: New York and Iowa	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Pharmacy, Inc. or one of its affiliates.